What's Happening?
Faeth Therapeutics has announced promising results from its Phase 2 DICE trial, which tested the combination of sapanisertib and paclitaxel in women with platinum-resistant ovarian cancer. The trial demonstrated
a 34% reduction in the risk of disease progression compared to paclitaxel alone, meeting its primary endpoint and supporting advancement to Phase 3. The combination extended progression-free survival by 45%, with manageable side effects. The trial's success suggests that targeting cancer cell metabolism can enhance the efficacy of existing therapies.
Why It's Important?
The findings from the DICE trial could significantly impact the treatment landscape for ovarian cancer, particularly for patients with limited options due to resistance to standard therapies. By improving progression-free survival and reducing disease progression risk, this combination therapy offers hope for better patient outcomes. The trial also highlights the potential of metabolic targeting in cancer treatment, which could lead to more effective and personalized therapies in the future.
What's Next?
The positive results from the Phase 2 trial justify a larger Phase 3 trial to further evaluate the efficacy and safety of the combination therapy. Ongoing analyses of response rates and overall survival, as well as biomarker evaluations, will help identify patients who may benefit most from this treatment. The success of this trial could pave the way for similar approaches in other cancer types.
